Published in Drug Law Weekly, July 26th, 2005
Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.
Amyloid beta 42 is a neurotoxic peptide that is the primary constituent of senile plaques that accumulate in the brains of patients with Alzheimer disease. It is thought to be the key initiator of Alzheimer disease since this peptide has the greatest tendency to aggregate, cause neuronal damage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.